Idiopathic pulmonary fibrosis: Securing a confident diagnosis for every patient

European Respiratory Journal

Volumn 47, Issue 4, 2016, Pages 1057-1059

  Jones, Mark G ^a,b   Walsh, Simon L F ^c   Jones, Kirk D ^d   Richeldi, Luca ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA6 INTEGRIN; BIOLOGICAL MARKER; NINTEDANIB; PIRFENIDONE;

COMORBIDITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; EARLY DIAGNOSIS; FIBROSING ALVEOLITIS; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; LUNG BIOPSY; MOLECULAR DIAGNOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; COMPUTER ASSISTED TOMOGRAPHY; IDIOPATHIC PULMONARY FIBROSIS; LUNG FIBROSIS;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PULMONARY FIBROSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84964057055     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00265-2016     Document Type: Review

References (15)

1. Liebow AA, Carrington DB. The interstitial pneumonias. In: Simmon M, Potchen EJ, Le May M, eds. Frontiers of Pulmonary Radiology. New York, Grune & Stratteon, 1969, pp. 102-141.
2. Raghu G, Collard HR, Egan JJ, et al. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med 2011; 183: 788-824.
3. Richeldi L, Bois du RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
4. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
5. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3-e19.
6. Yagihashi K, Huckleberry J, Colby TV, et al. Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. Eur Respir J 2016; 47: 1189-1197.
7. Walsh SL, Calandriello L, Sverzellati N, et al. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 2016; 71: 45-51.
8. Sigurdsson MI, Isaksson HJ, Gudmundsson G, et al. Diagnostic surgical lung biopsies for suspected interstitial lung diseases: A retrospective study. Ann Thorac Surg 2009; 88: 227-232.
9. Park JH, Kim DK, Kim DS, et al. Mortality and risk factors for surgical lung biopsy in patients with idiopathic interstitial pneumonia. Eur J Cardiothorac Surg 2007; 31: 1115-1119.
10. Hutchinson JP, Fogarty AW, McKeever TM, et al. In-hospital mortality following surgical lung biopsy for interstitial lung disease in the USA: 2000-2011. Am J Respir Crit Care Med 2015; [in press; DOI: 10.1164/rccm.201508-1632OC].
11. Tomassetti S, Wells AU, Costabel U, et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2015; [in press; DOI: 10.1164/rccm.201504-0711OC].
12. Kim SY, Diggans J, Pankratz D, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med 2015; 3: 473-482.
13. Saini G, Porte J, Weinreb PH, et al. αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease. Eur Respir J 2015; 46: 486-494.
14. Chien JW, Richards TJ, Gibson KF, et al. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. Eur Respir J 2014; 43: 1430-1438.
15. Britten N, Pope C, Halford S, et al. What if we made stratified medicine work for patients? Lancet Respir Med 2016; 4: 8-10.